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ABSTRACT 
A SIMULATION MODEL FOR BREAST CANCER EPIDEMIOLOGY IN TURKEY 
 
Kumru ADA 
M.S. in Industrial Engineering 
Supervisor: Asst. Prof. Özlem Çavuş 
Co-Supervisor: Prof. Dr. İhsan Sabuncuoğlu  
August 2014 
Breast cancer has a vital importance in women's life. In the world, breast cancer 
incidence and mortality rates are increasing. Considering the burden of disease, in 2012 
1.67 million women got breast cancer and about 522,000 women died due to breast 
cancer. With this numbers, breast cancer ranks as the most common cancer among 
women in the world and the fifth cause of death from cancer overall. Breast cancer has a 
high incidence and mortality rates especially in developing countries, where late 
diagnosis of cancer is also increasing the disease burden. Lack of knowledge of the exact 
causes of breast cancer increases the importance of early detection. The most effective 
way of early detection is to apply mammography screening. Screening the accurate 
target population increases the rate of early detection of breast cancer and lessens the 
economic and health burden of disease. In this study, two simulation models were 
constructed in order to analyze the population-based mammography screening programs 
for Turkey. The first model was run for 10 years for validation purpose while the second 
one was run for the women born in 1980 during their lifetime to analyze several 
screening programs. The screening programs differ from each other in terms of 
beginning and final age of screening and screening frequency. Costs and health 
outcomes of the screening policies were examined and non-dominated screening policies 
are determined according to these performance measures. 
Keywords: Breast cancer, screening programs, mammography, simulation 
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ÖZET 
TÜRKİYE’DE MEME KANSERİ EPİDEMİYOLOJİSİ SİMULASYON MODELİ 
Kumru ADA 
Endüstri Mühendisliği Yüksek Lisans 
Danışman: Yrd. Doç Dr. Özlem Çavuş 
Eş-Danışman: Prof. Dr. İhsan Sabuncuoğlu 
Ağustos 2014 
Meme kanseri kadınların hayatında yaşamsal bir öneme sahiptir. Dünyada meme kanseri 
görülme sıklığı ve ölüm oranları artmaktadır. Hastalık yükü olarak bakıldığında, 2012 
yılında 1.67 milyon kadın meme kanserine yakalanmış ve yaklaşık 522,000 kadın meme 
kanseri nedeniyle ölmüştür. Dünyada, meme kanseri kadınlar arasında en sık görülen 
kanser çeşididir ve kanser ölümleri arasında beşinci sıradadır. Özellikle gelişmekte olan 
ülkelerde meme kanseri görülme sıklığının ve ölüm oranlarının çok yüksek olmasının 
yanı sıra, meme kanseri teşhisinin geç evrelerde yapılmasına bağlı olarak hastalığın 
yükü de artmaktadır. Meme kanserinin kesin nedenlerinin bilinmemesi hastalığın erken 
teşhisinin önemini arttırmaktadır. Erken teşhisin en etkili yolu da tarama politikalarının 
uygulanmasıdır. Doğru risk grubundaki popülasyonu hedef alan bir tarama politikası, 
erken teşhis oranını arttırmakta ve kanserin hem ekonomik hem de sağlık yükünü 
azaltmaktadır. Bu çalışmada, Türkiye için toplum tabanlı tarama programları analiz 
edilmesi amacıyla, iki ayrı simülasyon modeli kurulmuştur. Modellerden ilki doğrulama 
amacıyla 10 sene için çalıştırılmış, diğeri ise farklı mamografi tarama politikalarının 
analizinin yapılması amacıyla, 1980 yılında doğan kadınlar için hayatları süresince 
çalıştırılmıştır. Tarama politikaları, mamografi taramasına başlama ve bitiş yaşı ve 
tarama sıklığı bilgilerine göre birbirlerinden farklılaşmaktadır.  Tarama politikalarının 
maliyet ve sağlık çıktıları incelenmiş ve baskın olan tarama politikaları bu performans 
ölçütlerine göre belirlenmiştir.   
Anahtar Kelimeler: Meme kanseri, tarama programı, mamografi, benzetim 
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Chapter 1 
 
Introduction 
 
Cancer is a group of diseases that cause body cells grow out of control by changing their 
form or structure [37]. If the abnormal and uncontrolled spread of cells is not controlled, 
cancer can cause death. Cancer is the third most common disease worldwide, while the 
first two ones are cardiovascular and infectious diseases [38].  
Cancer has shown an increase all over the world in recent years due to the increase in 
life expectancy and change in lifestyles, mostly in the western part. According to the 
World Health Organization’s statistical data, approximately 12 million people were 
diagnosed with cancer in 2008, and in 2030 this number is expected to increase to at 
least 26 million, which means 13.1 million more people for the year 2030 will be 
diagnosed with cancer [39].  
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Being the third most common disease worldwide, today, deaths due to cancer constitute 
13% of all deaths, which makes about 8.2 million people. The great majority of cancer 
deaths are related to [40]: 
 lung (1.59 million deaths/year) 
 stomach (723,000 deaths/year) 
 liver (745,000 deaths/year) 
 colorectal (694,000 deaths/year) 
 breast (521,000 deaths/year) 
 oesophageal (400,000 deaths /year) 
cancers. 
There are more than 200 different types of cancer and the most common types are: lung, 
stomach, liver, colorectal, and breast cancers, as stated above. These most frequent types 
differ between men and women. To give an example, breast cancer, a disease that 
formed in the tissues of the breast, is the leading cancer type among female population 
in the world. The percentage of breast cancer among other cancer types is 14.1% 
according to SEER data [42]. In developing countries, insufficient awareness of female 
population causes late diagnosis in majority of cases and this is the reason why breast 
cancer incidence rates are increasing in particular. In 2012, 1.67 women diagnosed with 
cancer and 522,000 of women died due to breast cancer [42]. The incidence rates of 
breast cancer are the highest in women aged 55-64 years, thus it is more likely to be seen 
in middle-aged or older women. Looking into the age groups of ten years, from 25 to 34, 
from 35 to 44, from 45 to 54, from 55 to 64, from 65 to 74, from 75 to 84 and greater 
than 85, the percentage of new cases are 1.8, 9.6, 22.2, 25.2, 20.7, 14.8, and 5.7, 
respectively [42]. The number of estimated new cases of breast cancer in U.S. is about 
295,000 in the year 2014 [43].  
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Constituting a significant percentage of all deaths around the world, the percentage of 
breast cancer specifically in all deaths caused by cancer is 6.9% [42]. It is estimated 
522,000 women died worldwide in 2012 due to breast cancer [41]. 
With Turkey in closer look, breast cancer is also the leading cancer type among female 
population, with an average incidence rate of 40.7/100,000 in 2013 which is given in 
Figure 1.  
 
Figure 1: Cancer Incidence Rates in Turkey (per 100,000) [44] 
In Turkey, breast cancer is the eighth most common death reason among female 
population, with a ratio of 2.1%, more than that of the U.S [4]. This leads us to the 
importance of early diagnosis and treatment in breast cancer.  
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Existing data show us that breast cancer incidence rate in the western part of Turkey is 
50/100,000, whereas it is 20/100,000 in the eastern part. This significant difference 
between two parts of Turkey is caused mainly by early menarche, late menopause, first 
birth > 30 years, less breast feeding, and other related factors [1]. 
Cancer statistics have not been evaluated accurately for years in Turkey. The exact 
incidence rates are hard to be assessed in Turkey because of the lack of regular screening 
record system. Then in 2004, transformation program in health was put into practice and 
cancer records became more reliable. That is, the cancer incidence rates increase in years 
thanks to the recovery in cancer statistics. However, taking into account the total cancer 
burden in Turkey, we find out that Turkey’s total cancer burden is behind the other 
countries and the health registry system needs to be improved. 
Unlike other cancer types, the probability of developing a breast cancer does not depend 
on the environmental risk factors. Prevention, early detection, diagnosis and treatment, 
and rehabilitation are some prominent methods of controlling breast cancer to develop. 
Exact causes of breast cancer are yet unknown. However, lack of activity, alcohol 
intake, overweight, tobacco usage, and obesity could have some impact in increasing 
breast cancer incidence rates. The statistical data collected by World Health 
Organization points out that reasons of increase in breast cancer rates are obesity, using 
of tobacco, and increase in elder population. There are some certain risk factors such as 
age, personal and family history, genetic alterations, reproductive and menstrual history, 
alcohol, obesity, and race [6]. 
Preventive activities are hard to implement since the causes of breast cancer are 
unknown. Thus, this is the reason that leads to the conclusion of the big importance of 
early detection and early treatment of the breast cancer, because it has the biggest 
respond ratio to the treatment. The earlier women are diagnosed for the breast cancer, 
the higher the rate of survival they have. In developed countries, if a woman is 
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diagnosed with breast cancer in the early stages, the 5 year survival rate is 80%. On the 
contrary, in developing countries, this rate is reduced to 40-60%. The success of breast 
cancer diagnosis by breast cancer screening methods in early stages is 63.7%. Early 
detection increases one’s 5-year survival rate up to 97.9% and it saves thousands of lives 
every year [4]. 
Early detection and starting treatment in early stages are the most effective way of 
reducing breast cancer mortality rates and relevant treatment costs. Breast cancer is 
detected by screening, before symptoms have developed or when a woman feels a breast 
abnormality. Clinical and self breast examinations, mammography, ultrasound, and 
magnetic resonance imaging are the methods of diagnosis. Mammography is the most 
successful tool for the early detection and moreover it is cheap, easy to apply and access. 
Use of these two or three screening methods together increases the effectiveness of 
screening. The efficiency of screening methods and the accuracy of the results are 
important since they directly affect the follow-up procedures as well as treatment costs.  
Breast cancer has the most significant incidence and mortality rates in the women, 
among all other cancer types. It is not possible to control breast cancer incidence rates 
by controlling relevant risk factors as it is not a risk factor dependent disease. Therefore, 
diagnosis of breast cancer in early stages gains meaning and the most efficient way to do 
this is mammography screening. Targeting the right population group ensures an 
increase in the number of early detection of breast cancers. Discussions about the 
optimal screening period are still ongoing; however the Ministry of Health of Turkey, 
Department of Cancer published breast cancer screening standards in 2004. According 
to these standards, proposed screening policy in our country is screening women aged 
50-69 every two years [14]. 
The purpose of this study is to analyze the advantages and disadvantages of the 
population-based mammography screening programs, to decide the initial and final 
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screening ages of women, and a good frequency of the screening program. We try to 
reduce screening, false positive and treatment costs, and mortality rates while detecting 
more breast cancer cases. In addition, we then examine the expected life years and 
quality adjusted life years of the screening programs. 
    17 
 
 
 
Chapter 2 
 
Literature Review 
 
Breast cancer is a leading disease among female population around the world and certain 
causes of it are unknown yet. Therefore, it is important to investigate the alternative 
solutions for reducing breast cancer incidence rates. The most effective way to do this is 
to spread breast cancer screenings.  
Breast cancer staging, is mainly about determining the presence and size of the tumor, 
and where positive lymph nodes are located. In the simulation model, breast cancer 
stages are assigned according to the SEER historical stages; (1) in situ, (2) localized, (3) 
regional, (4) distant stages. In situ stage is defined for tumors with negative nodes and 
below a critical size. The survival rate probabilities are extremely high for this stage. 
Once tumor reaches the critical size but still there are no positive nodes, the stage is 
called localized stage. If the critical size is exceeded and there is metastasis to the lymph 
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nodes, then the stage is called regional stage. Tumors with more than four positive nodes 
are defined as distant stage. As breast cancer spreads to the lymph nodes, the survival 
rates become lower. There are some in situ cancers which are not lethal. In addition, this 
kind of cancers does not show any progression [8].  
It is possible to categorize the most common methods for breast cancer screening into 
three parts: self-examination, clinical examination, mammography [45]. Breast self-
examination increases breast cancer awareness in women and helps them to understand 
the symptoms of breast cancer. Clinical breast examination has contribution to diagnose 
breast cancer early in women under the age of 40 years. Being used in addition to 
mammography, in women over the age of 40, this instrument helps early diagnosis of 
breast cancer. Finally, mammography screening is the most efficient way to diagnose 
and also the best tool to screen. In reality, it is inappropriate to apply all alternative 
screening policies and find the effective one considering the patients. Moreover, it 
would be quite costly even if it was applicable.  
Mammography has been proven to detect breast cancer at an early stage [15]. However, 
this tool has still some potential limitations [46]: 
- False negative results 
- False positive results 
- Over diagnosis and overtreatment 
- Radiation exposure 
- Pain and complications  
As stated, one of the important things is the performance of mammography screening. 
The sensitivity of mammography is the probability of a positive result among patients 
with disease and the specificity is the probability of a negative result among patients 
without breast cancer [47]. Sensitivity depends on tumor size, breast tissue density, 
patient age and also the image quality and skill of the radiologist. If the specificity is 
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low, it results in many false-positive mammography screening results. When false-
positive result probabilities become higher, it results in unnecessary follow-up 
examinations and procedures [48]. 
The screening guidelines vary from country to country; this is because of the 
characteristics of the female populations and their lifestyles. Furthermore, several major 
health organizations in the same country, namely the US, recommended different 
mammography screening policies (see Table 1).  
There are several studies in the operations research literature that consider optimization 
of cancer screening and diagnosis such as [20], [30], [31], [32], [33], [34], [35], [36]. We 
do not consider an optimization approach so our study is different than such studies. 
More information about these studies is available in [30]. 
In literature, the studies have been generally interested in breast cancer by medical 
terms. Only few studies consider the outputs of screening; such as, mortality, quality 
adjusted life years or cost considerations. Some of these studies are explained below. 
 
Table 1: Recommended Mammography Screening Policies and Organized Population-
Based Cancer Screening Programs [20] 
Institution/Country 
Initial 
Age 
Final  
Age 
Screening 
Frequency 
(Year) 
American Cancer Society, American Medical 
Association, American College of Radiology 
40 - 1 
National Cancer Institute 40 - 1-2 
US Preventive Services Task Force 50 74 2 
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American College of Preventive Medicine 50 - 1-2 
American Academy of Family Physicians 50 - 1-2 
American College of Obstetricians and 
Gynecologists 
40 - 
Age 40-49, 1-2 
Age 50+, 1 
Canada, Italy, Japan 50 69 2 
France, Netherlands 50 74 2 
Spain 45 69 2 
United Kingdom 50 70 3 
 
In U.S., a significant decline in breast cancer mortality rates was observed from 1989 to 
2000 [49]. Investigators want to determine whether this decline is a result of 
mammography screening or adjuvant therapy. For this reason, seven groups build their 
own models to estimate impact of screening and adjuvant therapy on population. The 
target group is modeled under some scenarios; such as, no screening and no adjuvant 
therapy, screening only, chemotherapy only, tamoxifen only, adjuvant therapy only, and 
screening and adjuvant therapy [27]. The observations, data, analysis technique and 
theories have an effect on the approach to modeling the system. The groups have met 
and discuss their findings since 2000 [27].  
In one of these studies by Fryback et al. [8], a discrete-event, stochastic simulation 
model is developed to model the breast cancer incidence and mortality in the U.S. 
population. The proposed Wisconsin Breast Cancer Epidemiology Simulation Model has 
four main processes; natural history of breast cancer, breast cancer detection, breast 
cancer treatment, and competing cause mortality. The main purpose is to answer the 
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questions about effectiveness of screening, treatment protocols, and to estimate benefits 
to women of specific ages and screening histories [8].  
Yılmaz and Yazıhan [4] have analyzed the economical benefits of breast cancer 
screening among women between 50 and 70 ages. This study only focuses on economic 
benefits of screening and neither considers life years and quality-adjusted life year 
effects of screening nor evaluates the economical benefits of alternative screening 
policies. What they only come up with in their study is to answer whether the women 
over the age of 50 are screened biennially is beneficial in terms of costs. 
A study by Ohnuki et al. [3] compares the cost-effectiveness ratio among three 
strategies: (1) annual clinical breast examination; (2) annual clinical breast examination 
combined with mammography; and (3) biennial clinical breast examination combined 
with mammography for Japanese women aged between 30–79 years. The study aims to 
search the economic efficiency of mammography screening between different age 
groups, and it also compares the economic efficiency of different screening methods. In 
this study, the mammography screening scenarios are selected according to age and 
screening interval. Annual and biennial policies are tested for all screening policies. The 
cost-effectiveness of different screening scenarios is found by running a simulation 
model. The simulation model is run for 15 years, costs and effects are collected. 
Another study in literature, by Wong et al. [2], tries to answer the question whether, for 
Chinese women ages between 40 and 79, the population based mammography screening 
is cost efficient or not. No screening strategy and 4 screening strategies (biennial 
screening of women between ages 40-69, 40-79, 50-69, 50-79) are compared in terms of 
costs, quality-adjusted life years saved and life years saved. They developed a Markov 
model by which mammography, diagnosis, and treatment are simulated and with the 
help of that the optimal screening age is tested. The model is run for 50 years and life 
expectancy, quality-adjusted life expectancy, and lifetime costs are collected to compare 
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the 5 different strategies; no screening, biennial screening of women between ages 50-
69, 50-79, 40-69 and 40-79 [2].  
A master thesis by Astım [6] analyzes population-based breast cancer screening policies 
and intends to determine the most cost-effective one. In that study, a simulation model is 
used to evaluate the cost-effectiveness of alternative breast cancer screening policies. A 
simulation model is run to obtain the costs and benefits of screening program. The study 
underlines the importance of breast cancer burden in terms of costs, while reduction in 
treatment costs and reduction in mortality and morbidity are taken as the benefit of the 
screening program. Screening policies are determined in terms of screening interval and 
minimum age to screen. Despite offering a biennial screening program for women over 
40 in Turkey; he does not look for the optimal screening program. Moreover, he 
considers neither outputs of screening policies from the women’s perspective nor age-
related effects of breast cancer progress and screening performance.  
There are numerous relevant clinical studies in Turkey. Most of them are limited with 
patients in a Turkish hospital or a sample of the population, for instance the female 
academicians in a university. Some of the subjects of these studies are summarized 
below: 
 Health beliefs in a certain section of female population 
 Knowledge of mammography and breast self-examination 
 Performing breast self-examination 
 Mammography device use in Turkey 
 Breast cancer diagnosis and treatment  
 Clinical outcome assessment in mammography 
In a study by Alpteker and Avcı [21], 38% of the participants (live in Karaköy, Bolu) 
had not even heard about breast self-examination and a majority (71.3%) of them had 
not known how to perform breast self-examination. Even the nursing students do not 
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have a complete belief and knowledge about the breast self-examination performance 
[23-24].  
A study among a group of women in rural area in western Turkey [22] showed that 
although 76.6% of participants reported that they had heard about breast cancer, only 
56.1% of them had sufficient knowledge about it. To summarize the findings of this 
study, 27.9% of participants had no knowledge about breast-self examination, %89.3 
had never had a mammography and 75% had never had a clinical breast examination.  
The knowledge and usage level of mammography are very low in Turkey. The 
participants in a study by Sadıkoğlu et al. [25] are women from the training hospital of 
the medical school in Bursa. It is found that 12.7% of women had no knowledge of 
mammography, 57.3% had never had a mammogram as a result of this study.   
The studies show that the knowledge and awareness of breast cancer among Turkish 
women are not sufficient. The importance of breast cancer incidence and mortality rates 
in Turkey has not known by Turkish women. Moreover, a majority of the population do 
not realize the significance of mammography screening and breast examination. Those 
who undergo mammography screening or do breast examination are a very little part of 
the population. These results clearly demonstrate the current situation in Turkey and 
increase the importance of the need of studies.  
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Chapter 3 
 
Problem Definition 
 
In the developed and developing countries, breast cancer is the most widespread cancer 
type and one of the primary causes of death among female population. High mortality 
rates and unnecessary follow-up procedures are the undesired results of breast cancer. 
With awareness among women, organized population-based screening programs provide 
early diagnosis of cancer, reduction in mortality rates and follow-up procedures. 
However, unless the importance of early diagnosis is known by the target population, it 
is hard to get any meaningful result from the screening programs. To get a good result, 
we emphasize the importance of the education of women and the awareness of cancer.  
In America and most of the European countries, government raises the awareness of 
female population about breast cancer thanks to their own breast cancer screening 
programs. In Turkey, there is no such screening program; moreover most of the women 
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do not have enough knowledge about breast cancer. Even though there are some training 
programs about raising awareness of this disease, they are not sufficient at all. 
In general, a healthy woman goes to a doctor for clinical examination at specific time 
intervals and if the woman is in target population, she takes mammography in specific 
intervals. Thus, early diagnosis of cancer may be possible in such a case. In our country, 
because of the lack of awareness, these procedures do not work in this way. Therefore, 
breast cancer is generally detected in later stages. 
As mentioned above, breast cancer is a disease that has significant reflections all around 
the world such as incidence rates, mortality rates, and related costs etc. There is no such 
a method to prevent or treat the breast cancer completely. Nevertheless, what we mean is 
that early diagnosis is an effective way to treat the breast cancer. Since the exact causes 
of the breast cancer are unknown, screening programs gain importance to detect, 
diagnose, and treat breast cancer.  
There are more than one breast cancer screening methods: digital mammography, 
magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, 
molecular breast imaging, and diffuse optical tomography. When abnormal results occur 
by using these screening tools, they should be followed up with diagnostic 
mammograms, ultrasound, or biopsy [46]. Mammography screening, the most common 
way of screening, has two types: Population-based mammography screening and 
patient-based mammography screening. Patient-based mammography screening 
programs target at achieving the aim of personalized medicine, in the basis of a more 
individualized approach which considers patient-specific features, such as age, breast 
density, and personal history. In population-based screening programs, a test is offered 
to all individuals in a defined target population according to a policy. The policy is 
selected according to specific features of the target population and target population is 
usually defined by age.  
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The preparation and implementation of the breast cancer early diagnosis and screening 
programs are planned and organized studies which are seriously needed. As a result of 
these studies, diagnosis in early cancer stages and mortality reduction can be possible.  
Population-based mammography screening programs have both harms and benefits. So, 
it is important to investigate the effects of screening programs before providing any 
recommendations on the issue. This study mainly aims at selecting the screening 
program for Turkey. Basically two central questions are to be answered while selecting a 
good scenario: what is the screening age interval and what is the frequency of screening? 
For this purpose, a realistic discrete-event simulation model is developed according to 
the epidemiology of breast cancer in Turkey. Initial and final ages of mammography 
screening and screening frequency will be determined through this model. In addition, 
the model is also used to study whether a decrease in breast cancer mortality among 
women in defined aged intervals is related to the scope of mammography screening. 
Effects of screening and diagnosis on incidence and mortality rates are to be analyzed.  
The different breast cancer screening policies are examined and compared with each 
other. Also, we try to answer the question how the total cost and quality-adjusted-life-
years (QALYs) are affected under different screening policies. Furthermore, the model 
will be analyzing how the epidemiology of breast cancer in Turkey changes if there is no 
practice of any screening policy.  
To briefly summarize, to develop a validated simulation model to analyze different 
screening policy recommendations for breast cancer is our contribution in this research. 
However, it is not possible to suggest one policy that effective in terms of all outcomes. 
Nevertheless, this study is useful in order to provide an opinion about the overall 
problem.  
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Chapter 4 
 
Model Development 
 
4.1 General 
The two simulation models are built in order to propose good breast cancer screening 
policies for Turkish women. These simulation models generate a cancer registry for the 
corresponding years. The inputs of the model are obtained from the literature; from the 
databases of SEER, World Health Organization, the Ministry of Health of Turkey, 
Turkish Institute of Statistics, and from the health record systems of Cancer Early 
Diagnoses and Treatment Centers. The purpose of this study is to evaluate the outcomes 
of different breast cancer screening policies and compare them with each other. 
Two simulation models are built. The first model is simulated between the years 2000-
2010 for the Turkish female population aged in the range of 30-79 years. The first model 
is run for approximately 14 million women, which is the female population in 2000, are 
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created in a single run. In each year of the interval 2000-2010, we add to the simulated 
cohort the women aged 30 years in that year and they stay in the system until they die 
due to the breast cancer or other reasons.  
The second simulation model tracks a cohort of cancer-free women aged 30 years in the 
year of 2010 over their lifetimes. Similar to the first model each women stays in the 
system until she dies or reaches the age of 100 years.  
 
4.2 Model 
The general flow chart of the first simulation model is given in Figure 2. In this figure, 
each year is represented by a loop. At time zero, which corresponds to the beginning of 
year 2000, we create all the female population aged between 30-79 years. At the 
beginning of the successive years, only the women at the age of 30 are created. All 
women are created as alive and at the time of creation, the attributes such as age, life 
status (being dead or alive), and cancer stages are assigned. Breast cancer can be 
detected by either mammography screening or clinical breast examinations. 
Created entities (the women) are transferred to the decision node where, with some 
probability, each woman dies due to the reasons other than the breast cancer. This death 
probability is estimated using the data obtained from Turkish Institute of Statistics for 
the years 2000-2010. An entity is either disposed from the system due to a death cause 
other than the breast cancer or transferred to the decision node where the clinical breast 
examination decision is made. In this node, if there is an abnormal finding as a result of 
clinical diagnosis, the entity is transferred to the treatment decision node.  
If there is not such a finding or there is no requirement for a clinical breast examination, 
the entity is re-sent to the decision node which decides whether the entity will have a 
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mammography screening or not, considering the screening strategy given before. If the 
screening is taken and the result is positive, meaning that mammography finds 
something abnormal, then the entity is transferred to the treatment decision node. If the 
screening is not taken or the result is negative, then the entity is sent to the tumor 
progress node.  
In the treatment node, the entity is disposed from the system due to either breast cancer 
or another reason. In the tumor progress node, basically a woman’s cancer status 
changes according to a Markov chain, which is an output of the study by Fryback et al. 
[8] and is adjusted for the situation in Turkey. The structure of the Markov chain is as 
follows: if the woman is diagnosed with a breast cancer, then the stage of the disease 
may stay the same, or progress to a later stage, or the woman may die. If the woman is 
not diagnosed with cancer, then she may stay healthy or she may have a breast cancer in 
her later ages. The details will be discussed in later sections. 
At the end of the year loop, corresponding counters are calculated and each entity’s age 
attribute is increased by one and entities are sent back to the top of the loop. The 
calculated counters are listed below: 
- Total incidence rates for each year 
- Incidence by stage for each year 
- Breast cancer mortality rates 
- Other causes mortality rates  
- The number of mammograms for each year 
- The number of true positive and false positive results for mammography 
- The number of clinical diagnosis 
- Total life year for each year 
- Quality adjusted life years for corresponding year 
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- Total cost for each year 
The second simulation model with the flow chart in Figure 3, basically has similar 
structure with the first simulation model, however, the entity creation and simulation 
length differ from the first simulation model. There is only one entity creation, which is 
at the beginning of the simulation as the number of living women with the age of 30 
years and over, and the simulation was run until they reach age 100. 
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Figure 2: Flow Chart of the First Simulation Model 
    32 
 
Create Woman as 
entity if woman is 
older than 30 
years old
Non BC 
mortality?
Dispose
Clinical Breast 
Examination?
Mammography 
Screening?
Positive 
Screening 
Result? 
Treatment
BC mortality? Dispose
Tumor Progress
Statistics
Increase Age by 
one
YES
YES
YES
YES
YES
NO
NO
NO
NO
NO
Positive 
Result?
YES
NO
 
Figure 3: Flow Chart of the Second Simulation Model 
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4.3 Model Data 
The methods we used to estimate the input data of the model are described below. 
4.3.1 Population 
The number of women that contributes to simulation for each year is the first and the 
most important input in order to run a simulation model and to discover the benefits of a 
population based breast cancer screening policy. 
The population data for the year 2000 are obtained from the population database of the 
Turkish Institute of Statistics (see Table 2). The database does not report the population 
of each age, instead groups the ages in increments of five years and reports the data 
accordingly. However, since every component of the simulation model depends on the 
age of the entity, we cannot use these data directly. To make things easier, the 
population of each age group is divided by five to generate the data needed for the 
simulation model.  
Table 2: Female Population in Turkey in 2000 
Age Group Female Population 
30-34 2,457,285 
35-39 2,400,808 
40-44 1,985,225 
45-49 1,658,012 
50-54 1,360,958 
55-59 1,042,168 
60-64 964,989 
65-69 850,636 
70-74 654,773 
75+ 603,977 
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As pointed out before, in the first model, the first entity creation is performed in the year 
2000 for the female population aged over 30 years. Then, at the beginning of the 
successive years, 30-year-old female population is added to the simulation cohort using 
the numbers given in Table 3, which are taken from the population database of the 
Turkish Institute of Statistics. In other words, in the year 2001, we create 502,465 
entities and add them to the system.  
Table 3: Number of Women at Age 30 in Turkey 
Year Number of Women at Age 30 
2001 502,465 
2002 513,472 
2003 524,480 
2004 535,487 
2005 546,495 
2006 557,502 
2007 568,507 
2008 574,118 
2009 582,514 
2010 612,751 
 
In the second simulation model, we only create the female population aged 30 in the 
year of 2010, which makes 612,751 women. And there is no entity creation for the 
successive years. 
4.3.2 Prevalence 
The overall breast cancer incidence rates for the years 2002-2008 are taken from the data 
of the Ministry of Health of Turkey (see Table 4). The estimation of the breast cancer 
incidence rates for the years 2009 and 2010 are also provided from Ministry of Health of 
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Turkey. The received data includes all live women at any age. However, because breast 
cancer is age-related and it generally appears after the age of 30, we calculated the 
incidence rates for the women over age 30. For this reason, overall incidence values for 
the women over 30 years are generated by calculating the product of each five-years-
age-group’s incidence rate (see Table 5) and its population (see Table 6), which also 
gives the number of women who has cancer (see Table 7). 
Table 4: The Reported Breast Cancer Incidence Rates by the Ministry of Health of 
Turkey for Female Population 
Year 
Overall 
Incidence  
(per 100,000) 
2002 31.96 
2003 33.93 
2004 34.7 
2005 35 
2006 37.6 
2007 35.9 
2008 36.5 
 
Prevalence is the actual number of cases alive and depends on both the incidence rates 
and the duration of the cancer.  
Therefore, we cannot directly use the incidence rates as prevalence because there are 
many women who are unaware of their growing disease hence these breast cancer cases 
are not diagnosed yet. In our simulation model the incidence rate value of the 2002 is 
used for the prevalence value at the year 2000 instead, which is the beginning year of the 
simulation. In other words, in the simulation model the probability of having breast 
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cancer in the year 2000 is calculated by using the incidence rate at the year 2002 and the 
female population in the year 2002. 
 
Table 5: Breast Cancer Incidence Rates Estimated by the Ministry of Health of Turkey 
for all Female Population for Every Five-Year-Age-Group (per 100,000) 
Age Group 2002 2003 2004 2005 2006 2007 2008 
0--4 0 0 0 0 0 0 0 
5--9 0 0 0 0 0 0 0 
10--14 0 0 0 0 0.2 0 0 
15--19 0.5 0.5 0 0.2 0 0.2 0.2 
20--24 1.2 1.5 0.9 2.1 0.8 2.2 2.4 
25--29 5.5 6.1 7.2 7.2 6.5 6.7 6.9 
30--34 16.4 20.5 19.8 19.2 18.6 16.1 16.1 
35--39 38.7 37 44.1 44.4 40.7 40.8 41.2 
40--44 67.9 76.2 75.3 68.5 80.9 74 75.1 
45--49 90 100.5 91.6 88.6 100.1 96.2 97.3 
50--54 115.1 104.1 93.3 102.8 106 101.4 99.3 
55--59 114 112.7 100.6 108.4 110 111 110.5 
60--64 119.7 111.3 117.9 117.9 123.2 116.6 116.1 
65--69 103.5 120 99.9 94.3 119.3 112.2 113.7 
70--74 119.8 138.4 87.7 85.8 109.7 104.7 102.4 
75--79 125 125.1 123.1 117.6 99.4 109.2 106.7 
80--84 72.2 111.2 79.7 132.4 162.7 94.7 99 
85+ 62.8 40.1 78.3 75.7 71.8 71.5 73 
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Table 6: Female Population in Turkey 
Age 
Group 
2002 2003 2004 2005 2006 2007 2008 2009 2010 
30--34 2,567,360 2,622,398 2,677,435 2,732,473 2,787,510 2,842,548 2,870,589 2,912,568 3,063,753 
35--39 2,431,243 2,446,460 2,461,677 2,476,894 2,492,112 2,507,329 2,649,543 2,740,457 2,767,247 
40--44 2,088,442 2,140,051 2,191,660 2,243,269 2,294,877 2,346,486 2,342,544 2,296,915 2,249,976 
45--49 1,763,563 1,816,338 1,869,113 1,921,888 1,974,664 2,027,439 2,130,748 2,228,411 2,341,378 
50--54 1,482,010 1,542,536 1,603,062 1,663,588 1,724,114 1,784,640 1,818,561 1,847,369 1,835,058 
55--59 1,149,903 1,203,770 1,257,638 1,311,505 1,365,373 1,419,240 1,454,659 1,483,667 1,649,342 
60--64 999,717 1,017,081 1,034,444 1,051,808 1,069,172 1,086,536 1,153,037 1,236,594 1,301,377 
65--69 869,717 879,257 888,797 898,337 907,878 917,418 917,704 920,652 958,566 
70--74 680,220 692,943 705,666 718,389 731,113 743,836 699,248 736,844 787,768 
75+ 771,074 854,623 938,172 1,021,721 1,105,269 1,188,818 1,136,990 1,031,173 1,250,373 
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Table 7: The Estimated Breast Cancer Incidence Rates for Female Population over Age 
30 in Turkey  
Year 
Overall Incidence  
(per 100,000) 
2002 74.06391 
2003 77.51916 
2004 72.59213 
2005 73.61959 
2006 79.79504 
2007 75.89705 
2008 75.86695 
2009 76.07786 
2010 76.3435 
 
When the simulation is over, the incidence rate outputs of the model are compared with 
the data taken from the Ministry of Health of Turkey. This comparison will be discussed 
in later sections. 
4.3.3 Mortality 
In the model, death depends on breast cancer or other causes. At the end of each year if 
the woman is dead, meaning life status is zero, she leaves the system; else she lives and 
goes back to the beginning of the year loop. The number of target population which is 
given as input, updates itself at the beginning of each year by subtracting dead 
population from the all given population. This is why; the probability of death needs to 
be calculated. 
Turkish Institute of Statistics publishes the statistics of both the number of dead 
population and reasons of deaths every year (see Table 8). The probability of death is 
    39 
 
basically calculated by dividing the number of the dead female population by the 
corresponding year’s female population. Decision whether the entity leaves the system 
or continues is taken according to the derived probability.  
Table 8: The Number of All Deaths for Female Population in Turkey by Age 
Group and by Year 
Age 
Group 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
30-34 831 773 792 908 870 799 856 821 815 1514 1432 
35-39 1,103 1,170 1,054 1,139 1,037 1,066 1,084 1,074 1,140 2,046 1,900 
40-44 1,520 1,441 1,481 1,599 1,649 1,622 1,745 1,613 1,633 2,707 2,496 
45-49 2,042 2,121 2,088 2,301 2,113 2,306 2,225 2,296 2,457 3,991 3,779 
50-54 2,826 2,755 2,926 3,338 3,006 3,182 3,363 3,296 3299 5,098 4,865 
55-59 3,574 3,334 3,316 3,851 3,620 4,198 4,229 4,208 4,242 6,676 6,465 
60-64 5,494 5,452 5,641 5,779 5,287 5,384 5,646 5,275 5,740 9,056 9,323 
65-69 8,211 7,920 7,593 7,679 7,300 8,326 8,507 8,381 7,930 12,764 12,408 
70-74 11,113 10,963 11,053 11,723 11,492 11,348 11,620 11,373 11,000 17,879 18,583 
75+ 28,053 29,071 31,304 33,511 34,565 38,036 42,913 45,203 47,541 86,602 89,423 
 
In the simulation model, the number of deaths due to breast cancer is also going to be 
used, so to prevent double counting, the probability of death from breast cancer is 
subtracted from the derived death probability. These non-related-to breast cancer death 
probabilities are used to find how many women will die at the beginning of each year 
from a reason other than breast cancer, which are called deaths due to the causes other 
than the breast cancer. The number of deaths in women due to breast cancer is gathered 
from Death Statistics which Turkish Institute of Statistics published in 2008 (see Table 
9). 
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Table 9: The Number of Breast Cancer Deaths for the Female Population in Turkey 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
The 
number 
1,136 1,225 1,176 1,175 1,268 1,615 1,752 1,761 1,809 2,043 2,215 
 
Entities stay in the system until they are completely disposed by the probability of death 
due to either breast cancer or another reason.  
4.3.4 Screening 
Entities are dispatched into two paths when they come to mammography screening 
component. They continue with either screening or not screening path. The screening 
decision (see Figure 4) is made according to the chosen screening policy and attributes 
of the corresponding entity. 
 
Result Negative
Result Positive
Cancer 
No Cancer
Cured
Died
Cancer with 
Symptom
Cured
Died
Result Negative
Result Positive
Cancer with 
Symptom
Cancer 
No Cancer
 
Figure 4: Structure of the Screening Decision 
(Reproduced from Ohnuki et al. [3]) 
    41 
 
The screening probabilities that whether the woman is going to be screened or not are 
found by using the data from the report of the Ministry of Health of Turkey, called 
Health Statistics Yearbook (2010). In this report, the number of mammography taken is 
given from year 2007 to 2010 which is given in Table 10. By using this data, the rate of 
taking mammography for the women aged 30 and over is calculated for 2007 to 2010. In 
this step we use linear regression method to estimate the rates of mammography taken 
for 2000 and 2006. Then, the number of mammograms taken is found by multiplying the 
corresponding year’s female population and these rates (see Table 10).  
Table 10: The Number of Mammograms Taken in Turkey 
Year The Number of Mammograms Taken 
2000 121,417 
2001 237,399 
2002 359,819 
2003 488,679 
2004 623,977 
2005 765,715 
2006 913,892 
2007 940,055 
2008 1,367,201 
2009 1,495,665 
2010 1,456,347 
 
Tunçbilek et al. [10] mention the number of mammograms taken for screening and 
medical diagnosis reasons. In her article, the result shows us that 91% of the 
mammograms are taken for screening purpose, and other 9% is taken for medical 
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diagnosis reasons. In our study, the data taken from Cancer Early Diagnoses and 
Treatment Centers’ report are updated with this information. That is, the number of 
mammograms taken is multiplied by 0.91 to find the number mammograms taken for 
only screening purpose.  
Cronin et al. [9] mention the ratios of annual mammograms taken for ages 18-39, 40-49, 
50-59, 60-69, and 70-79. With this information, the number of annual mammograms 
taken for ages 30-39, 40-49, 50-59, 60-69, 70+ is generated. The probability of being 
screened is calculated by dividing the number of mammograms taken to the female 
population for each age group. By using these probabilities, the screening decisions are 
made for every woman. If no screening decision is made, then entity is transferred to 
other components. Else, the result of the mammography screening is determined whether 
it is positive or not.  
The mammography result of being false positive or true negative is determined by using 
specificity values which is given in article of Kerlikowske et al. [7]. An entity’s true 
positive mammography result means that a woman is actually diagnosed by breast 
cancer and the stage of the cancer should be decided [50]. Despite of the cancer status, if 
the result is positive, then the entity is transferred to the treatment component. If the 
result is negative, then the entity is transferred back to the beginning of the loop for 
simulation of the next year by increasing age attribute by one. Mammography specificity 
and sensitivity values which are given in Table 11 are taken from Kerlikowske et al. [7]. 
Table 11: Sensitivity and Specificity of Screening Mammography According to Age 
Age 30-39 40-49 50-59 60-69 
Sensitivity in women with no 
family history, % 
69.5 77.5 80.2 87.7 
Specificity in women with no 
family history, % 
91.3 88.9 89.3 89.7 
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4.3.5 Markov Chain 
If cancer is diagnosed by screening or clinical examination, patients are transferred to 
the cancer progress module. There is a Markov chain process in here (see Figure 5). 
Markov chain manages the actions which are the progress of cancer and deaths due to 
breast cancer.  
As mentioned before, size of the tumor and presence of positive nodes determine the 
stage of cancer. In this study the critical size of the tumor and the fraction of the non-
fatal in situ cancers are used from the study by Fryback et al. [8].  Each year, a woman 
will make a transition to 1 to 4 breast cancer stages, or they will die or remain cancer-
free. Women who are diagnosed with breast cancer at any stage have a higher risk of 
death compared to healthy women. This Markov chain is taken from Fryback et al. [8] as 
an initial data and updated by some estimation for the situation in Turkey and the death 
probabilities from article Chhatwal et al. [32]. In every loop, transition probabilities vary 
for each entity due to various factors like age, chosen screening strategy and whether the 
patient has been diagnosed before or not. 
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Healthy (cancer-
free)
In situ Local Regional Distant
Non Fatal Stage I
Death due to 
breast cancerDeath due to other 
causes
 
Figure 5: Markov Chain Model 
(Modified from Wong et al. [2]) 
 
4.3.6 Clinical Breast Examination 
Detectability of the cancer is mainly about the tumor size. The probability of detecting 
distant cancer is much more than the probability of detecting in situ. The decision 
whether one’s being clinically diagnosed or not, is defined by using the values from 
Fryback et al. [8]. Although the given data are appropriate for the case of women with 
the knowledge of breast cancer, it is not valid for the situation in Turkey. Studies that 
raising the awareness of women is limited in our country. Because of that, this data need 
to be adjusted for Turkey. For this adjusting process, firstly the studies in our country are 
examined. In a study by Eryılmaz et al. [11], the self-checked breast examination rate is 
18% for the women applying to Konya Early Diagnosis Scanning and Education 
Centers. Another study [16] is about evaluating the breast self examination rate of 
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female academicians in a Turkish University. And as a result, it is seen that only 27.7% 
of participants performed breast cancer examination regularly. In the light of these 
studies, it is not appropriate to take the same clinically diagnosed probability rate in U.S. 
for Turkey. For this purpose, the clinically diagnosis probabilities of the in situ, local 
and regional cancer are reduced by the results of the studies mentioned above. The 
probability is left the same for distant cancer, because it is impossible not to notice and 
detect the distant stage of breast cancer. By doing this, the input data are derived from 
literature for Turkey model. If a woman is clinically diagnosed, then she is transferred to 
the treatment module.  
 
Figure 6: Clinical Diagnose Model 
(Reproduced from Rojnik et al. [54]) 
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4.3.7 Treatment 
If a patient’s mammography result is positive, meaning being an abnormal module, or 
patient is diagnosed clinically, that is, after the cancer is diagnosed, entity is transferred 
to the treatment component. In this component, the entity leaves the system due to breast 
cancer death or a reason other than the breast cancer death. In the treatment component, 
the probability of breast cancer death is calculated differently from the probabilities in 
Markov chain.  
The method and success of the treatment depend on breast cancer estrogen receptor 
status. Estrogen Receptor-Positive (ER+) cancer cells depend on estrogen for their 
growth and can be treated with hormone therapies like tamoxifen and aromatase 
inhibitors to reduce either the effect of estrogen or the actual level of estrogen. ER+ 
tumors have better survival rates than tumors with Estrogen Receptor-Negative (ER-) 
[51].   
To calculate breast cancer death probabilities under treatment, firstly the ratios of ER+ 
and ER- are needed [17]. In Chhatwal et al. [32], the reduction of breast cancer death 
probabilities for each stage is given, whether the tumor is ER+ and ER-, for 50-, 50-69, 
70+ age groups. The percentage of reduction is used to find the probabilities of breast 
cancer deaths for local and regional cancer stages under treatment for corresponding age 
groups. The probability of breast cancer death under treatment for in situ and distant 
cancer stages are used the same as the probability of undiagnosed breast cancer death. In 
the first place, the breast cancer death probability for in situ cancer stage is 0. The 6 
month probabilities are needed for the model and these probabilities are obtained for one 
year, so there is a need to transform these probabilities. To do this transformation, firstly 
we have to find the percentage of breast cancer death reduction for each stage when the 
treatment is applied. By using the data of breast cancer death probabilities with no 
treatment and the reduction rates from Mariotto et al. [28] and the ratios of ER+ and ER- 
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data from Çalıkapan [17], the breast cancer death probabilities under treatment for each 
stage are calculated. These probabilities are for 1 year cycle. Therefore, the cycle for 6 
months is found by applying the formulas below: 
                       , t=1 
                        , t=1/2 
We found α values for each stage of cancer by using one year probabilities in the first 
formula and by using the α values in second one we calculated the six-months 
probabilities of breast cancer death under treatment. 
4.3.8 Costs 
Preventive health services improved the quality and quantity of individuals and beside of 
this cause a significant reduction in the cost of treatment as a result of early diagnosis. 
The most important parameter defining the cost of treatment for a patient is the stage of 
cancer at the diagnosis, as it directly affects the medical intervention methods [6]. The 
cancer diagnosed in later stages has more aggressive and costly treatment processes. 
Most of the studies also clarify that breast cancer treatment costs depend considerably on 
the progress of the disease [4,52]. 
The study by Astım [6] is used for calculating the cost values for this study. According 
to this thesis, the cost of mammography screening per woman is 15.2 TL.  The data used 
in that study are collected from the cost structures analyzed by Cancer Early Diagnosis 
and Treatment Centers. If mammography screening is performed and the result is false 
positive, then further treatment costs for false positive results are 58 TL in 2007 prices. 
Once woman is diagnosed by breast cancer either by screening or clinically, 
corresponding treatment cost is added to the total costs. The treatment costs for each 
stage of cancer per patient are also used from the same study. In Astım [6], these data 
are obtained from Yılmaz and Yazıhan [4].  
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Cost data of 2007 is used in Astım [6]. Then these costs are escalated from year 2007 to 
2013 by using published inflation data of Turkish Institute of Statistics our study. Costs 
adjusted to the 2013 level are shown in Table 12. 
 
Table 12: Cost Data (TL) 
Average Screening Cost Per Patient 23.9  
Average Treatment Cost Per Patient 
Stage I 4,053.2  
Stage II 5,693.3  
Stage III 13,722.6  
Stage IV 6,285.5  
False Positive Result Cost Per Patient 91.1  
 
4.3.9 Life Years Gained 
This effect is an outcome measure in economic evaluations of health interventions. Life 
years gained (LYs gained) is calculated by looking only being alive or dead without 
distinguishing between young or adult population. LYs gained measure is calculated for 
every year in the simulation model. This value is calculated using the formula given 
below: 
                       
                                              
                                                   
Dividing total life years gained to the number of women at the beginning of the 
corresponding year results in life year value per woman.    
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4.3.10 Quality-Adjusted Life Years (QALY) 
Quality adjusted life year methodology is one of the measurements of the life quality 
lost due to the disease. QALY is calculated by taking into consideration of both the 
quantity and quality of life affected by healthcare interventions [6]. It is basically the 
combination of quantity and quality of life lived. It provides an assessment of health 
related quality of life resulting by health interventions [6]. Every health states have 
utility weights which are located between 1 and 0. Normally, the best health state, 
perfect health, has a weight of 1. However, the score of perfect health state will 
generally count less than 1 since it can change easily by some factors, such as; age or 
current health situation of the woman. In this study, the perfect health state is valued in 
Table 13 basically due to woman’s age. To calculate QALYs, we multiply life years 
spent in a given health state by the quality of life score for that health state. The worst 
health state, meaning death, has a weight of 0. 
Table 13: QALY Score of a Healthy Woman 
Age Score 
30-40 0.893 
40-50 0.863 
50-60 0.837 
60-70 0.811 
70-80 0.771 
80+ 0.724 
 
The QALY combines mortality and morbidity into a single measure and it allows us to 
compare alternative screening policies for the same condition. In most of the studies, 
QALYs lost due to breast cancer are calculated for each phase. Three different factors 
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affect the utility score calculation; taking a mammography, getting a positive 
mammography result and having breast cancer.  
In this research, these QALY disutility values due to having cancer are calculated from 
Stout [26]. The lost values of QALYs are 0.1, 0.1, 0.25 for two years, 0.4 until death for 
each cancer stage respectively. That is, QALY lost is low when the cancer is diagnosed 
in early stages and much higher in other stages. If a woman dies, the QALY value is 
equal to 0. QALY lost depends in a great extent on the treatment procedure carried on. 
Since the treatment methodology selected is related to the stage of the breast cancer in 
diagnosis, QALY is also dependent on the diagnosis stage [6]. When a mammography is 
taken, a disutility value is subtracted from the QALY score of the women irrespective of 
the mammography result. In addition, also a disutility score due to a positive 
mammography result is subtracted from the current QALY score. Having breast cancer 
has also a disutility score, which is again subtracted from the QALYs score of women as 
well. The formula we used to calculate QALYs is provided below: 
     
                                                                
                                                                     
                         
                                                      
                                     
In the simulation model, QALY lost per person is calculated by dividing the total QALY 
values by the number of women alive for corresponding year. 
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Chapter 5 
 
Results 
 
The first simulation model is run for validation purpose. The second model is 
constructed to analyze the alternative screening policies for Turkish female population. 
5.1 Validation 
As explained above, we use several data sources; previous studies in the literature, the 
records of some institutions in Turkey. Some of the model input parameters derived 
from literature for our model and some of them were adjusted to make simulation output 
match as closely as possible to the data of Turkey.  
Firstly, we calibrate the model in order to fit the simulation output to the observed 
incidence rate data of Ministry of Health of Turkey and breast cancer mortality rate data 
of Turkish Institute of Statistics. Cancer registry in Turkey has started in recent years 
and not yet fully implemented as required. Therefore, we collected the input data from 
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different sources. Because of this, it is normal not to come from the simulation model 
with incidence rates which are quite close to the incidence rate data of Ministry of 
Health. As described previously, the Markov chain and breast cancer mortality rate were 
adjusted in order to conform as much as possible to the current data in Turkey. The 
reported incidence rate data and simulation output can be seen in Table 14 and Figure 7. 
The simulation outputs are based on the average of 10 replications. The incidence rates 
obtained from the simulation model are generally higher than the reported incidence 
rates. This is an expected result; since the data collected in Turkey are not very reliable 
because of undiscovered or unreported breast cancer cases. 
 
Table 14: Overall Incidence Rates (per 100,000) for Validation 
Year 
Reported Incidence 
Rates 
Average Simulation 
Output 
95% Confidence 
Interval 
2002 74.064 90.582 [89.352 , 92.582] 
2003 77.519 92.593 [91.489 , 93.842] 
2004 72.592 94.936 [94.235 , 96.057] 
2005 73.620 95.526 [93.981 , 96.801] 
2006 79.795 96.029 [94.849 , 97.414] 
2007 75.897 96.280 [94.855 , 97.518] 
2008 75.867 94.989 [93.580 , 97.110] 
2009 76.078 100.665 [99.110 , 101.926] 
2010 76.344 99.915 [98.425 , 101.668] 
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Figure 7: Breast Cancer Incidence Rates (per 100,000) 
 
Ministry of Health of Turkey provides the breast cancer incidence rates by age for the 
years 2002 and 2010; the incidence rates of the years 2008-2010 come from the 
estimated data. We obtained the average breast cancer incidence rates by age groups by 
running the simulation model for 10 replications and compared them with the reported 
ones. As seen in Figure 8-17, the obtained rates are generally higher than the reported 
ones. 
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Figure 8: Breast Cancer Incidence Rates for Women Aged Between 30-34 (per 100,000) 
 
 
Figure 9: Breast Cancer Incidence Rates for Women Aged Between 35-39 (per 100,000) 
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Figure 10: Breast Cancer Incidence Rates for Women Aged Between 40-44 (per 
100,000) 
 
 
Figure 11: Breast Cancer Incidence Rates for Women Aged Between 45-49 (per 
100,000) 
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Figure 12: Breast Cancer Incidence Rates for Women Aged Between 50-54 (per 
100,000) 
 
 
Figure 13: Breast Cancer Incidence Rates for Women Aged Between 55-59 (per 
100,000) 
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Figure 14: Breast Cancer Incidence Rates for Women Aged Between 60-64 (per 
100,000) 
 
 
Figure 15: Breast Cancer Incidence Rates for Women Aged Between 65-69 (per 
100,000) 
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Figure 16: Breast Cancer Incidence Rates for Women Aged Between 70-74 (per 
100,000) 
 
 
Figure 17: Breast Cancer Incidence Rates for Women Aged Over 75 (per 100,000) 
 
The reliability of the collected data is a common problem since the registries for the 
health system are not sufficient in Turkey. Turkish Institute of Statistics publishes the 
number of deaths according to age, gender, cause of death for province and distant 
centers in Turkey every year (see Table 15). The death certificates are the main 
information available for keeping statistics about the causes of deaths. 
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Table 15: Breast Cancer Mortality Rates for Validation (per 100,000) 
Year 
Reported Breast Cancer 
Mortality Rates 
Average Simulation 
Output 
2002 7.944 19.404 
2003 7.722 26.840 
2004 8.114 32.613 
2005 10.069 37.368 
2006 10.649 40.274 
2007 10.442 42.180 
2008 10.534 43.729 
2009 11.602 44.506 
2010 12.165 45.012 
 
There are some studies about the proportion of the notification of the correct cause of 
deaths. In one of these studies, Etiler et al. [13] did a research that compares the death 
certificates sent from Kocaeli University Hospital to State Statistics Institute with patient 
records. The deaths between 2002 and 2003 were included in this study and it was found 
that only 31.7% of the cause of death on the certificate was correctly written. The result 
of the study shows that; exact causes of deaths were reported wrongly which means the 
accuracy of death certificates is low. Having such a large deviation in the data of a 
university hospital constitutes a question mark about the death reasons occurring outside 
the hospitals. This situation raises a question mark over the true rank of cancer in the 
ranking of death causes. 
In another study by Işık et al. [19], it is stated that about 70% of death of causes are 
reported incorrectly. They mentioned that the exact causes of deaths are not correctly 
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reported even in university hospitals. The lack of studies about the notification of the 
cause of deaths in our country may indicate the indifference on this issue. 
Based on these studies explained above, it would not be wrong to think the breast cancer 
mortality rate output of the simulation would be much higher than the data collected and 
published every year (see Table 15 and Figure 18).  In addition, while the mortality rates 
are examined for other countries, the breast cancer mortality rate between the years 
2006-2010 is 22.6/100,000 in the U.S. and the rate in 2011 is 24.6/100,000 in the UK. 
The breast cancer awareness in these countries is higher and hence more people can 
reach mammography screening and treatment compared to Turkey. In this case, it is 
expected that breast cancer mortality rate is higher in Turkey than these countries. 
 
 
Figure 18: Breast Cancer Mortality Rates (per 100,000) 
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5.2 Computational Results and Analysis 
5.2.1 Screening Policies 
Real life applications have played a role in the selection of these policies. Some of the 
policies are taken from the literature; some of the policies are the ones applied by other 
countries and one of them shows the current situation in Turkey. The proposed screening 
policy in Turkey is to do mammography screening in every two years for the female 
population aged between 50-69 [14]. The data of the current situation in Turkey is taken 
from the database of the Ministry of Health of Turkey. In this study, the screening 
policies are implemented under the full participation assumption. That is, the screening 
processes are applied for the whole female population specified in corresponding policy. 
For instance, for the 40-69 annual screening policy, the whole female population aged 
between 40 and 69 are screened annually. 
Three features are taken into account while distinguishing the screening policies: the 
initial and final ages of screening and its frequency. In the second simulation model, 
initial screening ages are selected as 30, 40, 45, 50 and final ages are selected as 69, 74, 
and 79. The details of screening policies are given in Table 16. In one of the policies, 
there is no implementation of any screening program, which is called do nothing policy. 
The other screening policies consist of annual, biennial, and triennial screening 
frequencies.  
Table 16: Screening Policies  
Policy 
Initial  Age 
of Screening 
Final Age of 
Screening 
Frequency of Screening 
(Year) 
30-79 annual 30 79 1 
30-79 biennial 30 79 2 
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Policy 
Initial  Age 
of Screening 
Final Age of 
Screening 
Frequency of Screening 
(Year) 
30-79 triennial 30 79 3 
40-69 annual 40 69 1 
40-69 biennial 40 69 2 
40-69 triennial 40 69 3 
40-74 annual 40 74 1 
40-74 biennial 40 74 2 
40-79 annual 40 79 1 
40-79 biennial 40 79 2 
45-69 biennial 45 69 2 
50-69 annual 50 69 1 
50-69 biennial 50 69 2 
50-69 triennial 50 69 3 
50-74 annual 50 74 1 
50-74 biennial 50 74 2 
50-79 biennial 50 79 2 
Do Nothing No screening 
 
The choice of screening frequency is important, because it directly affects the related 
costs and the benefits for women. If the screening frequency is low, then it means there 
is enough time to develop cancer cells. Also cancer cells can progress between two 
screening intervals. On the other hand, even though there is a slightly lower reduction in 
mortality rates; higher screening frequency may cause higher rates of inaccurate positive 
results and higher screening costs.  
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5.2.2 Results 
The simulation model is built by the integrated development environment Dev C and run 
for different screening policies to get the outputs given below: 
 Total incidence rates for each year 
 Incidence rates by stage for each year 
 Breast cancer mortality rates 
 Mortality rates due to reasons other than breast cancer  
 The number of mammograms taken for each year 
 The number of true positive and false positive results for mammography 
 The number of clinical diagnoses 
 Total life year per person for each year  
 Quality adjusted life years per person for corresponding year 
 The cost of applying treatment 
 The cost of mammography taken 
 The cost of false-positive results 
 Total cost per person for each year 
In addition to these results, effectiveness of alternative screening policies and relative 
costs are obtained from the simulation. The following results are very much dependent 
on the applied screening policy. In these results, the average data are calculated by 
taking average of 70 years. 
One of the important results is the incidence rates of breast cancer. Analyzing the breast 
cancer incidence rates for cohort born in 1980 and for different screening policies shows 
us the importance of screening. An increase in the number of screened women results in 
higher breast cancer incidence rates, since there will be more diagnose cases. The results 
of simulation runs also support this situation (see Table 17 and Figure 19). Doing 
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mammography screening annually to the target population of the ages from 30 to 79 
creates the highest average incidence rate. Similarly, for instance; when we look at the 
policies that have a 3 year mammography screening frequency, the policy which has the 
highest average incidence rate is the one with the larger age interval, namely screening 
female population aged 30-79 annually.  
Table 17: Average Incidence Rates of Breast Cancer for 1980 Cohort (per 100,000) 
Screening Policy Average Incidence Rates 
30-79 annual 160.58 
30-79 biennial 158.08 
30-79 triennial 154.46 
40-69 annual 148.95 
40-69 biennial 147.73 
40-69 triennial 142.74 
40-74 annual 153.63 
40-74 biennial 150.82 
40-79 annual 159.08 
40-79 biennial 156.23 
45-69 biennial 144.53 
50-69 annual 143.68 
50-69 biennial 141.62 
50-69 triennial 139.69 
50-74 annual 148.62 
50-74 biennial 146.00 
50-79 biennial 141.80 
do nothing 120.77 
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Figure 19: Average Incidence Rates (per 100,000) 
 
Another important result is the breast cancer stage diagnosis ratio (see Table 18 and 
Figure 20). Since the mammography screening provides early detection of breast cancer; 
it is expected that, an increase in the number of mammograms will increase the 
likelihood of early detection. That is, the bigger difference between initial and final 
screening ages and smaller screening frequency mean high number of mammograms. 
Our results in Table 18 support that expectation. When the policies that have same initial 
and final screening ages are examined, it can be seen that the breast cancer early 
diagnosis ratio is higher as the screening frequency is low. Similarly, for the policies 
with the same screening frequency, the one that has smaller initial age and higher final 
age, namely 30-79, has a higher early diagnosis ratio.  
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Table 18: Breast Cancer Stage Diagnosis Ratio of Each Screening Policy for 1980 
Cohort (percentage) 
Screening Policy Stage I Stage II Stage III Stage IV 
do nothing 0.0383 0.1578 0.2266 0.5773 
50-69 triennial 0.2595 0.1865 0.1926 0.3614 
50-69 biennial 0.2877 0.1894 0.1859 0.3370 
40-69 triennial 0.2944 0.1853 0.1798 0.3404 
50-74 biennial 0.3026 0.1921 0.1876 0.3177 
50-69 annual 0.3242 0.1890 0.1802 0.3067 
45-69 biennial 0.3324 0.1891 0.1771 0.3014 
40-69 biennial 0.3374 0.1797 0.1655 0.3174 
50-79 biennial 0.3567 0.1913 0.1739 0.2782 
50-74 annual 0.3914 0.1873 0.1567 0.2646 
40-74 biennial 0.3923 0.1928 0.1653 0.2496 
30-79 triennial 0.3986 0.2026 0.1658 0.2329 
40-69 annual 0.4111 0.1846 0.1496 0.2546 
40-79 biennial 0.4351 0.1985 0.1538 0.2125 
30-79 biennial 0.4581 0.1966 0.1502 0.1950 
40-74 annual 0.4638 0.1878 0.1425 0.2059 
40-79 annual 0.5033 0.1899 0.1299 0.1768 
30-79 annual 0.5263 0.1891 0.1278 0.1567 
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Figure 20: Breast Cancer Stage Diagnosis Ratios (percentage) 
 
Other result obtained from the second simulation model is mortality rates due to breast 
cancer. Screening more women means early diagnosis of the cancer and early diagnosis 
means higher survival rates with better treatment. Thus the mortality rates could be less 
while the number of diagnosed women is increased. Table 19 is supporting this 
statement. It is more effective to screen as many as females to reduce the number of 
deaths due to breast cancer. According to the results of simulation model (see Table 18 
and Figure 21), a good screening policy for reducing the breast cancer mortality rate is 
to screen the female population aged 30-79 annually as expected.   
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Table 19: Mortality Rates Due To Breast Cancer among Female Population for 1980 
Cohort (per 100,000) 
Screening Policy 
Average Mortality Rate Due To 
Breast Cancer 
30-79 annual 42.57 
30-79 biennial 50.77 
30-79 triennial 57.56 
40-69 annual 55.43 
40-69 biennial 62.22 
40-69 triennial 67.37 
40-74 annual 50.00 
40-74 biennial 58.53 
40-79 annual 45.86 
40-79 biennial 54.42 
45-69 biennial 66.16 
50-69 annual 65.74 
50-69 biennial 69.12 
50-69 triennial 72.38 
50-74 annual 58.21 
50-74 biennial 65.46 
50-79 biennial 70.35 
do nothing 91.16 
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Figure 21: Breast Cancer Mortality Rates (per 100,000) 
 
Other results obtained from simulation runs are related to costs. Screening more women 
and screening frequently resulted in an increase in costs, especially in screening costs 
and cost of false positive results. The higher number of women is discussed in annual 
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policy has the highest total cost, as we can see in Table 20 and Figure 22.  
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Table 20: Costs by Screening Policy for 1980 Cohort (TL) 
Screening 
Policy 
Average 
Screening 
Costs 
Average Cost 
of False 
Positive 
Results 
Average 
Treatment 
Costs 
Average Total 
Cost 
30-79 annual 
637,381,390 290,831,868 319,471,519 1,247,684,777 
30-79 biennial 
324,450,961 150,083,521 332,727,688 807,262,170 
30-79 triennial 
220,130,670 104,336,231 335,628,952 660,095,852 
40-69 annual 
391,219,778 164,593,806 309,881,747 865,695,331 
40-69 biennial 
202,391,858 86,430,632 321,564,999 610,387,489 
40-69 triennial 
135,542,879 58,784,843 322,532,575 516,860,297 
40-74 annual 
446,747,065 185,595,578 315,484,234 947,826,878 
40-74 biennial 
224,639,780 95,031,581 325,709,080 645,380,441 
40-79 annual 
492,011,983 203,061,352 320,946,197 1,016,019,532 
40-79 biennial 
251,722,213 105,927,507 332,192,187 689,841,907 
45-69 biennial 
160,535,248 67,278,820 320,946,478 548,760,545 
50-69 annual 
249,059,147 100,263,915 312,082,129 661,405,190 
50-69 biennial 
131,229,458 53,466,768 317,354,978 502,051,204 
50-69 triennial 
91,893,022 37,695,780 319,357,301 448,946,104 
50-74 annual 
304,621,488 122,021,233 316,832,739 743,475,461 
50-74 biennial 
153,525,783 62,336,605 323,678,733 539,541,121 
50-79 biennial 
103,050,402 42,238,081 322,127,193 467,415,676 
do nothing 
0 0 295,833,369 295,833,369 
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A shift from annual screening to biennial screening or from biennial to triennial 
screening policy cause a decrease in the screening costs and accordingly in the cost of 
false positive results because of a decrease in the number of screened women. The 
treatment costs depend on the number of women who are diagnosed with breast cancer 
either by clinical examination or mammography screening. For “do nothing” policy, 
clinical examination is the only way to get diagnosed. That is, the number of clinically 
diagnosed women constitutes the treatment cost for “do nothing” policy. “Do nothing” 
policy has the minimum total cost. 
 
 
Figure 22: Screening, Treatment, False Positive Result and Total Costs 
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There are two different types of outcomes that occur by introducing a policy: cost and 
effectiveness outcomes. A policy can be cheaper or more expensive than other policies 
and it can be better or worse than the other policies. Being better means having more 
saved lives, more cures or higher life years gained. For a policy compared to the existing 
one, it can cost more or less and it can be better or worse. 
 
Figure 23: The Space of Policies 
 
The space of policies consists of four quadrants (see Figure 23). Outcomes located in 
Quadrant I are more effective and more expensive, those in Quadrant II are less effective 
and more expensive, those in Quadrant III are less effective and less expensive, and 
those in Quadrant IV are more effective and less expensive [53]. For being an effective 
policy, the policy needs to be more effective and less expensive comparing with the 
other policies.  
The total cost of screening policies and the relevant outcome (in this study the outcome 
is used as Quality adjusted life year (QALY) values) are used in order to determine the 
non-dominated policies. Health outcomes and costs can be discounted to adjust for time 
differences. They are discounted for giving more weight to immediate over distant 
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outcomes, meaning reflecting the fact that future costs and effects are less valuable. 
When we compare the policies we use undiscounted performance measures but 
discounted ones can also be used. The data collected for this analysis are given in Table 
21 and Table 22. 
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Table 21: LY, QALY and Cost Data for 1980 Cohort 
 
Screening 
Policy 
Total 
Average LY 
Disc. 
Average LY 
Total 
Average 
QALY 
Disc. 
Average 
QALY 
Average 
Total Cost 
(TL) 
Disc. 
Average Cost 
(TL) 
30-79 annual 31,168,943 15,971,308 25,615,124 13,522,989 1,247,684,777 433,285,439 
30-79 biennial 31,070,887 15,940,387 25,546,709 13,503,735 807,262,170 264,475,178 
30-79 triennial 30,984,925 15,911,663 25,481,575 13,481,973 660,095,852 208,539,611 
40-69 annual 31,014,781 15,920,086 25,504,490 13,488,277 865,695,331 236,242,574 
40-69 biennial 30,947,407 15,898,580 25,454,899 13,473,053 610,387,489 161,911,493 
40-69 triennial 30,889,038 15,878,964 25,409,567 13,457,474 516,860,297 135,660,042 
40-74 annual 31,061,725 15,929,720 25,538,307 13,495,295 947,826,878 244,141,636 
40-74 biennial 30,980,773 15,905,444 25,479,995 13,478,293 645,380,441 165,385,272 
40-79 annual 31,084,343 15,934,091 25,554,804 13,498,488 1,016,019,532 249,010,297 
40-79 biennial 30,989,565 15,907,064 25,486,215 13,479,448 689,841,907 168,644,353 
45-69 biennial 30,883,985 15,872,284 25,404,985 13,451,853 548,760,545 132,369,479 
50-69 annual 30,838,632 15,855,903 25,368,715 13,437,956 661,405,190 142,532,377 
50-69 biennial 30,809,731 15,847,422 25,349,015 13,432,350 502,051,204 110,631,990 
50-69 triennial 30,766,895 15,834,726 25,315,691 13,422,316 448,946,104 99,583,904 
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Screening 
Policy 
Total 
Average LY 
Disc. 
Average LY 
Total 
Average 
QALY 
Disc. 
Average 
QALY 
Average 
Total Cost 
(TL) 
Disc. 
Average Cost 
(TL) 
50-74 annual 30,881,108 15,864,797 25,400,117 13,444,587 743,475,461 150,429,699 
50-74 biennial 30,834,075 15,852,519 25,367,019 13,436,185 539,541,121 114,271,225 
50-79 biennial 30,780,137 15,837,300 25,325,676 13,424,313 467,415,676 101,453,286 
do nothing 30,522,872 15,767,393 25,131,093 13,369,600 295,833,369 65,986,884 
 
Table 22: LY, QALY and Cost Data for 1980 Cohort (per Person) 
 
Screening 
Policy 
LY per 
Person 
QALY per 
Person 
Cost per 
Person (TL) 
Disc LY per 
Person 
Disc QALY 
per Person 
Disc Cost per 
Person (TL) 
30-79 annual 50.8672 41.8035 2,036.20 26.0649 22.0693 707.1150 
30-79 biennial 50.7072 41.6918 1,317.44 26.0145 22.0379 431.6193 
30-79 triennial 50.5669 41.5855 1,077.27 25.9676 22.0024 340.3334 
40-69 annual 50.6156 41.6229 1,412.80 25.9813 22.0127 385.5442 
40-69 biennial 50.5057 41.5420 996.14 25.9462 21.9878 264.2370 
40-69 triennial 50.4104 41.4680 843.51 25.9142 21.9624 221.3951 
40-74 annual 50.6922 41.6781 1,546.84 25.9971 22.0241 398.4353 
40-74 biennial 50.5601 41.5830 1,053.25 25.9574 21.9964 269.9062 
    76 
 
Screening 
Policy 
LY per 
Person 
QALY per 
Person 
Cost per 
Person (TL) 
Disc LY per 
Person 
Disc QALY 
per Person 
Disc Cost per 
Person (TL) 
40-79 annual 50.7292 41.7050 1,658.13 26.0042 22.0293 406.3809 
40-79 biennial 50.5745 41.5931 1,125.81 25.9601 21.9982 275.2249 
45-69 biennial 50.4022 41.4605 895.57 25.9033 21.9532 216.0249 
50-69 annual 50.3282 41.4013 1,079.40 25.8766 21.9305 232.6106 
50-69 biennial 50.2810 41.3692 819.34 25.8627 21.9214 180.5497 
50-69 triennial 50.2111 41.3148 732.67 25.8420 21.9050 162.5194 
50-74 annual 50.3975 41.4526 1,213.34 25.8911 21.9414 245.4989 
50-74 biennial 50.3207 41.3986 880.52 25.8711 21.9276 186.4888 
50-79 biennial 50.2327 41.3311 762.82 25.8462 21.9083 165.5702 
do nothing 49.8128 41.0135 482.80 25.7321 21.8190 107.6896 
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Firstly we need to order the alternative screening policies (see Table 23 and Figure 24). 
Then dominated alternatives need to be deleted. For instance, screening the female 
population between the ages of 50-74 biennially, 50-69 annually, 50-74 annually, and 
45-69 biennially screening policies are dominated by triennial screening between the 
ages 40-69. That is, these policies are deleted due to extended dominance. Similarly, 
some screening policies are deleted because of extended dominance. At the end of these 
deletions, do nothing, 50-69 triennial, 50-79 biennial, 50-69 biennial, 40-69 triennial, 
40-69 biennial, 40-74 biennial, 30-79 triennial, 40-79 biennial, 30-79 biennial, 40-79 
annual, and 30-79 annual screening policies are left (see Table 24 and Figure 25). 
Whereas annual screening between ages 30-79 is the most effective in QALY and do 
nothing policy is found to require the lowest total cost. 
 
Table 23: QALY-Total Cost (TL) Data for 1980 Cohort for All Alternative Screening 
Policies 
Screening  
Policy 
QALY  
(per person) 
Average Total Cost 
(TL) 
(per person) 
do nothing 41.01354867 482.7954085 
50-69 triennial 41.31481047 732.6729843 
50-79 biennial 41.33110468 762.815035 
50-69 biennial 41.36919364 819.3396725 
50-74 biennial 41.39857596 880.5226276 
50-69 annual 41.40134353 1079.402873 
50-74 annual 41.45259211 1213.340265 
45-69 biennial 41.46053616 895.5685838 
40-69 triennial 41.46801365 843.5078797 
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Screening  
Policy 
QALY  
(per person) 
Average Total Cost 
(TL) 
(per person) 
40-69 biennial 41.54199525 996.1427879 
40-74 biennial 41.58295174 1053.250735 
30-79 triennial 41.58553009 1077.266055 
40-79 biennial 41.59310195 1125.811149 
40-69 annual 41.62292744 1412.801173 
40-74 annual 41.67811579 1546.838565 
30-79 biennial 41.69182721 1317.439172 
40-79 annual 41.70503854 1658.127905 
30-79 annual 41.80348026 2036.201943 
 
 
Figure 24: QALY-Total Cost for All Alternative Screening Policies 
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Table 24: QALY-Total Cost (TL) Data for 1980 Cohort for Non-Dominated Screening 
Policies 
Screening  
Policy 
QALY  
(per person) 
Average Total Cost (TL) 
(per person) 
do nothing 41.01354867 482.7954085 
50-69 triennial 41.31481047 732.6729843 
50-79 biennial 41.33110468 762.815035 
50-69 biennial 41.36919364 819.3396725 
40-69 triennial 41.46801365 843.5078797 
40-69 biennial 41.54199525 996.1427879 
40-74 biennial 41.58295174 1053.250735 
30-79 triennial 41.58553009 1077.266055 
40-79 biennial 41.59310195 1125.811149 
30-79 biennial 41.69182721 1317.439172 
40-79 annual 41.70503854 1658.127905 
30-79 annual 41.80348026 2036.201943 
 
    80 
 
 
Figure 25: QALY-Total Cost for Non-Dominated Screening Policies 
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Chapter 6 
 
Conclusion 
 
Cancer is one of the leading health problems and the third death reason all around the 
world. Lung, liver, stomach and colon cancers are common among men whereas breast, 
lung, colon, and stomach cancers are common among women. It is no doubt that 
countries should handle reducing the impact of cancer which affects the whole society. 
Breast cancer is by far the most common cancer diagnosed in women with a proportion 
of 23% of all new cancer cases. It has the most important incidence and mortality rates 
for females in other countries and Turkey as well. In many European countries, breast 
cancer incidence rates are low for women under the age of 50. Because of the high rate 
of false positive and false negative results, generally screening is recommended as the 
initial age of 50. In Turkey, age of breast cancer is younger than European countries, 
besides cancers are detected in later stages [52]. Therefore, breast cancer incidence rates 
and age distribution have shown huge differences between countries. Because of this, 
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early detection programs should be organized according to the characteristics of the 
population of each country.  
Unlike other cancer types exact causes of breast cancer are unknown and there are not 
any environmental risk factors like lung cancer or stomach cancer. The major risk factor 
for lung cancer is tobacco usage or incidence rates of stomach cancer may be reduces by 
a diet. However, breast cancer cannot be easily controlled like these. As above 
mentioned, cancer is a disease that has expensive detection and treatment costs, thus 
sometimes the economic burden of the disease may be more than the overall disease 
burden. At this point, applying the right screening programs gain importance. Screening 
has the most important role, because decreasing breast cancer mortality rates can be 
done by early diagnosis. Screening individuals means spending money but it has long 
term benefits. 
For the implementation of screening programs in the community, especially knowledge 
and awareness of the target population for breast cancer should be increased. That is, 
target female population should know that breast cancer is the most common disease for 
them. For this purpose, the most important goal should be to educate women about it and 
to explain the importance of the disease.  
The screening method generally applied in our country is made of opportunistic 
mammography screening. In this method, women are guided for mammography 
screening or for clinical examination by their doctors or people around them. Therefore, 
the method of screening is not effective since it cannot be done at regular intervals or by 
invitation. Experienced and educated workers, long-term budget, resources and a well-
defined target population are needed for implementation of population-based screening 
program. Implementation of population-based screening programs is quite difficult. 
In this thesis, a real world simulation model is built to evaluate and compare the 
outcomes of different mammography screening policies. The most important outcomes 
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can be summarized as quality-adjusted life years, life years, breast cancer mortality 
rates, and total cost. The data from literature, Turkish Institute of Statistics and the 
Ministry of Health of Turkey are used to find the outcomes of simulation model. In this 
context, two simulation models were constructed; one is run for 10 years for the 
validation purpose and the other one is run until the women aged 30 reach the age of 100 
in order to analyze different screening policies.  
Implementation of mammography screening is an effective method for breast cancer but 
at the same time it is costly. It is important to design an effective mammography 
screening program while considering the health benefits and harms of mammography. 
As a result of a previous study by Astım [6], the suggested screening policy for 
economic efficiency is to screen women over 40 biennially. In this study, different 
screening policies become applicable according to the output taken into account. Since, 
as mentioned above, while considering the breast cancer mortality rate outcome, the 
effective policy is screening annually the female population aged between 30 and 79, 
considering the total cost outcome, do nothing policy is become effective. That means 
the decision regarding the relative importance of different outcomes is left to the 
decision makers. 
Nevertheless, there are some shortcomings of this study, summarized below: 
 Lack of data sources in Turkey 
 Including one type of screening method (mammography) 
 Not running for all possible policies and choosing a good policy by terms 
of selected outcomes 
 Questions regarding to the applicability of the screening policies due to 
insufficient medical centers, equipments and employees 
One of the important shortcomings is insufficient data. We have to borrow most of the 
input data from different sources (literature, U.S. data etc.) because of a serious dearth of 
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local data. The simulation models should be run by using local data. Additionally, 
although the age-specific breast cancer incidence rates are low compared to the 
European countries, almost half of the patients are diagnosed with breast cancer under 
the age of 50. In this sense, there is an important need to national data especially for the 
women older than 40 years old. As a result of using national data, a precise screening 
policy can be made.  
Another shortcoming of this study is the simulation models are constructed based on 
only mammography screening. However, there are many alternative screening methods 
and mammography screening should be supported by these methods. That is, simulation 
models should be arranged for alternative screening methods as well. 
The number of all feasible screening policies in terms of initial/final age of screening 
and screening frequency is very large. For this reason, the analysis of all these feasible 
policies becomes compelling. Therefore, we have not considered all of them.  
Another major topic is applicability of screening policies. Practically, to implement the 
selected screening policy, there will be enough resources such as; medical centers, 
employees and equipments. Additionally, enough budgets should be allocated for this 
purpose.  
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